Mont-Saint-Guibert (Belgium), October 9, 2024, 10:35 pm CET / 4:35 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contact:
Nyxoah
Loic Moreau, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.71 |
Daily Change: | -0.37 -6.09 |
Daily Volume: | 93,114 |
Market Cap: | US$213.730M |
March 26, 2025 March 13, 2025 February 19, 2025 November 06, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load